U.S. Markets closed

3x5 Partners Closes Third Fund at $100 Million

·2 min read

The Fund will invest in healthcare and climate solutions

3x5 Partners ("3x5") has closed 3x5 Partners Fund III, LP ("3x5 Fund III") with $100 million in capital commitments. 3x5 is a venture capital firm that collaborates with passionate entrepreneurs to deliver better healthcare and climate solutions. Their healthcare investments include biotechnology, medical devices and diagnostic companies. The firm addresses environmental challenges through investments in companies with innovation for water, energy, food, and waste.

Based in Portland, Oregon, 3x5 has raised over $400 million and has delivered both top returns to investors and meaningful impact to the world. Investments include:

  • SOURCE – The world’s first renewable drinking water system that is clean, safe, and entirely off-grid

  • Allakos – Biotechnology company developing allergic and inflammatory therapeutic antibodies

  • Rubicon – Software platform providing corporate and municipal smart waste and recycling solutions

  • Smart Wires – Maximizing the grid’s transfer capacity to accelerate affordable, clean energy

  • Vapotherm – Non-invasive respiratory technology for patients with mild to severe respiratory distress

"Our goal has always been to significantly improve the lives of people and help humanity be better stewards of the planet. Protecting the shared health of the planet and its people is more critical than ever. We believe deeply that, far from being an encumbrance, investing in essential solutions is the source of our performance," states Nicholas Walrod, co-founder and Managing Director at 3x5. "We at 3x5 are incredibly thankful to individuals, families, and institutions who have trusted us with their capital. We will continue to serve as business building partners for our entrepreneurs, generate top returns for our limited partners, and deliver breakthrough solutions for our world."

In service of 3x5’s mission to "invest in what the world needs", 3x5 Fund III is already an investor in five companies: Adarza BioSystems, Arch Oncology, Fervo Energy, Good Therapeutics, and Intervene. 3x5 is committed to building companies with patient capital and believes that prioritizing what is best for the portfolio companies also ultimately leads to the best outcomes for investors. With careful assembly of a high-conviction portfolio, 3x5 leads early financing rounds, aims to be an active board member, and deploys $15M-$20M per company.

3x5 Partners was founded in 2011 by Tony Arnerich and Nicholas Walrod. 3x5 Partners’ venture funds include 3x5 Special Opportunity Fund, LP, 3x5 RiverVest Fund II, LP and 3x5 Partners Fund III, LP. In addition, 3x5 has raised and managed numerous SPVs.

About 3x5 Partners

With over $400 million raised, 3x5 Partners is a venture capital firm that collaborates with passionate entrepreneurs developing solutions to our global health and climate crises. Established in Portland, Oregon in 2011, 3x5 has delivered both top returns to investors and meaningful impact to the world. More information is available at www.3x5partners.com

View source version on businesswire.com: https://www.businesswire.com/news/home/20210316005295/en/


Nicholas Walrod